UA115683C2 - Комбінована терапія для лікування госпітальної пневмонії - Google Patents

Комбінована терапія для лікування госпітальної пневмонії

Info

Publication number
UA115683C2
UA115683C2 UAA201507554A UAA201507554A UA115683C2 UA 115683 C2 UA115683 C2 UA 115683C2 UA A201507554 A UAA201507554 A UA A201507554A UA A201507554 A UAA201507554 A UA A201507554A UA 115683 C2 UA115683 C2 UA 115683C2
Authority
UA
Ukraine
Prior art keywords
treatment
combination therapy
nosocomial pneumonia
nosocomial
pneumonia
Prior art date
Application number
UAA201507554A
Other languages
English (en)
Ukrainian (uk)
Inventor
Шампа ДАС
Цзяньґо Лі
Йохан Віллем Моутон
Райт Ніколс
Original Assignee
Пфайзер Енті-Інфектівз Аб
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50114393&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA115683(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Пфайзер Енті-Інфектівз Аб filed Critical Пфайзер Енті-Інфектівз Аб
Publication of UA115683C2 publication Critical patent/UA115683C2/uk

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41841,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/529Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim forming part of bridged ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53831,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/65Tetracyclines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/7036Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
UAA201507554A 2013-02-06 2014-02-06 Комбінована терапія для лікування госпітальної пневмонії UA115683C2 (uk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361761369P 2013-02-06 2013-02-06
PCT/GB2014/050354 WO2014122468A1 (en) 2013-02-06 2014-02-06 Combination therapy for the treatment of nosocomial pneumonia

Publications (1)

Publication Number Publication Date
UA115683C2 true UA115683C2 (uk) 2017-12-11

Family

ID=50114393

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201507554A UA115683C2 (uk) 2013-02-06 2014-02-06 Комбінована терапія для лікування госпітальної пневмонії

Country Status (13)

Country Link
US (1) US20150374673A1 (enExample)
EP (1) EP2953626A1 (enExample)
JP (1) JP6383367B2 (enExample)
KR (1) KR20150115761A (enExample)
CN (2) CN110302203A (enExample)
AU (1) AU2014213795B2 (enExample)
BR (1) BR112015018360B1 (enExample)
CA (1) CA2897446A1 (enExample)
CL (1) CL2015002180A1 (enExample)
MX (1) MX2015010077A (enExample)
RU (1) RU2684112C2 (enExample)
UA (1) UA115683C2 (enExample)
WO (1) WO2014122468A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112017010132B1 (pt) * 2014-11-17 2023-02-14 Entasis Therapeutics Limited Combinações e seus usos no tratamento de infecções bacterianas resistentes
WO2016156346A1 (en) 2015-03-31 2016-10-06 Mutabilis Heterocyclic compounds and their use in preventing or treating bacterial infections
KR20170131661A (ko) 2015-09-16 2017-11-29 수안주 파마 코포레이션 리미티드 β-락타메이즈 억제제 및 이의 용도
US20200316083A1 (en) * 2016-06-17 2020-10-08 Wockhardt Limited Antibacterial compositions
KR102667828B1 (ko) 2016-09-16 2024-05-20 엔타시스 테라퓨틱스 리미티드 베타-락타마제 억제제 화합물
US10434089B2 (en) 2017-01-25 2019-10-08 The Johns Hopkins University Avibactam and carbapenems antibacterial agents
NZ758200A (en) 2017-05-08 2025-12-19 Entasis Therapeutics Inc Compounds and methods for treating bacterial infections
US11905286B2 (en) 2018-08-09 2024-02-20 Antabio Sas Diazabicyclooctanones as inhibitors of serine beta-lactamases
TWI764030B (zh) 2018-08-09 2022-05-11 法商安塔比奧公司 化合物
RU2746833C1 (ru) * 2020-08-03 2021-04-21 Федеральное государственное бюджетное образовательное учреждение высшего образования "Волгоградский государственный медицинский университет" Министерства здравоохранения Российской Федерации ФГБОУ ВО ВолгГМУ МЗ РФ Способ моделирования экспериментального воспаления легких у крыс
CN113413367A (zh) * 2021-08-16 2021-09-21 浙江尖峰药业有限公司 一种注射用阿维巴坦头孢甲肟复方粉针及其制备方法
GB202306826D0 (en) 2023-05-09 2023-06-21 Adjutec Pharma As Therapy
CN119818504A (zh) * 2025-01-04 2025-04-15 重庆圣华曦药业股份有限公司 一种头孢哌酮和阿维巴坦的抗菌组合物及其用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008524204A (ja) * 2004-12-17 2008-07-10 ヴィーナス・レメディーズ・リミテッド 感染の処置に全面的解決を与えるための抗生物質の組合せ
CN101074235B (zh) * 2006-05-15 2010-05-12 中国药品生物制品检定所 头孢硫脒醇水化合物及其制备方法
CN101245080A (zh) * 2007-02-14 2008-08-20 山东轩竹医药科技有限公司 含有吡唑并三唑的头孢菌素衍生物
CA2754677A1 (en) * 2009-03-26 2010-09-30 Pulmatrix, Inc. Methods for treating and preventing pneumonia and ventilator-associated tracheobronchitis

Also Published As

Publication number Publication date
RU2015132369A (ru) 2017-03-13
CL2015002180A1 (es) 2015-11-27
BR112015018360A2 (pt) 2017-07-18
JP2016507547A (ja) 2016-03-10
EP2953626A1 (en) 2015-12-16
WO2014122468A1 (en) 2014-08-14
CN104994860A (zh) 2015-10-21
KR20150115761A (ko) 2015-10-14
AU2014213795B2 (en) 2016-10-13
MX2015010077A (es) 2016-01-25
RU2684112C2 (ru) 2019-04-04
CN110302203A (zh) 2019-10-08
AU2014213795A1 (en) 2015-07-30
BR112015018360B1 (pt) 2022-03-22
CA2897446A1 (en) 2014-08-14
US20150374673A1 (en) 2015-12-31
JP6383367B2 (ja) 2018-08-29

Similar Documents

Publication Publication Date Title
UA115683C2 (uk) Комбінована терапія для лікування госпітальної пневмонії
PH12020551397A1 (en) Cot modulators and methods of use thereof
PH12019501321A1 (en) Methods of treating or preventing cholesterol related disorders
JOP20190194A1 (ar) مركبات نيوكليوتيدات ثنائية حلقية لعلاج السرطان
PH12015501954A1 (en) Anti-b7-h4 antibodies and immunoconjugates
MX2022011140A (es) Metodos novedosos.
MX2016015181A (es) Combinacion de un anticuerpo del receptor 4 de quimiocina anti-cc y un agonista de 4-1 bb para el tratamiento del cancer.
MX2016003129A (es) Terapia de combinacion de anticuerpos contra el csf-1r humano y anticuerpos contralel pd-l1 humano.
JOP20140141B1 (ar) استخدام 3،2- ثنائي هيدروإيميدازول-[2،1-c] كونازولينات مستبدلة لمعالجة الاورام الليمفاوية
MX2016014306A (es) Marcadores para terapia con lipoproteinas de alta densidad (hdl).
NZ710444A (en) Compositions and methods for treating neurodegenerative diseases and cardiomyopathy
WO2014165090A8 (en) Compounds for the treatment of tuberculosis
MX2017017124A (es) 6-amino-quinolin-3-carbonitrilos como moduladores de cancer osaka tiroides (cot).
MY178390A (en) Inhibitors of iap
GEP20196984B (en) Pyridazine derivatives for use in the prevention or treatment of an ataxic disorder
PH12016501173A1 (en) Quinazolin-thf-amines as pde1 inhibitors
CL2015002358A1 (es) Compuestos bicíclicos.
EA201790687A1 (ru) Хинолинкарбоксамиды для применения в лечении множественной миеломы
JO3628B1 (ar) كينازولين مهلجن-thf-أمينات على هيئة مثبطات pde1
MY172369A (en) Microorganism of the genus escherichia producing l-tryptophan and method for producing l-tryptophan using the same
GEP201706795B (en) Hexahydrofuropyrroles as pde1 inhibitors
MX2016004573A (es) Inhibidores de nsp4 y metodos de uso.
NZ711523A (en) Use of sedoheptulose for prevention or treatment of inflammation
PH12016500541A1 (en) Use of odiparcil in the treatment of a mucopolysaccharidosis
NZ750581A (en) Compositions and methods for treating neurodegenerative diseases and cardiomyopathy